Efficacy of combined Xeloda/Taxotere regimen in metastatic breast cancer

Taxotere and Xeloda have been previously shown to be effective in metastatic breast cancer when prescribed as a single drug in addition, some studies have demonstrated their synergism in breast cancer. During the present study, we have used a combined Xeloda/Taxotere regimen in metastatic breast cancer patients who have never been on either drug.

Twelve breast cancer patients who have been on anthracycline regimen and had at least one measurable metastatic site were included. They were put on the following regimen: Taxotere 75mg/m2 for the first day and Xeloda 1000mg/m2 twice a day for 14 days. This protocol was repeated 3 times with 3 weeks interval between each phase. Metastatic sites were reevaluated following the course of therapy.

Of 12 patients, 4 have shown a complete response and 3 partial response. Myelosuppression was the most frequent drug side effect presenting in 5 patients.

Combined regimen of Xeloda/Taxotere was found to be more effective than the single drug regimen. The side effects are acceptable.